Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients

BACKGROUND: Metastatic melanoma is an aggressive form of skin cancer with a high mortality rate and the fastest growing global incidence rate of all malignancies. The introduction of BRAF/MEK inhibitor combinations has yielded significant increases in PFS and OS for melanoma. However, at present, no...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Hematol Oncol
Autors principals: Daud, Adil, Gill, Japinder, Kamra, Sheily, Chen, Lei, Ahuja, Amit
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2017
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5209913/
https://ncbi.nlm.nih.gov/pubmed/28052762
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-016-0369-8
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars